Prospective study on late renal toxicity following postoperative chemoradiotherapy in gastric cancer
- PMID: 17157445
- DOI: 10.1016/j.ijrobp.2006.09.012
Prospective study on late renal toxicity following postoperative chemoradiotherapy in gastric cancer
Abstract
Purpose: Postoperative chemoradiotherapy in gastric cancer improves locoregional control and survival. Reports on late toxicity, however, have been scarce thus far. Because renal toxicity is one of the most serious late complications in upper abdominal radiotherapy, we prospectively analyzed kidney function in patients who underwent postoperative chemoradiotherapy for gastric cancer.
Patients and methods: In 44 patients, Tc99m-thiatide renography was performed before and at regular intervals after postoperative chemoradiotherapy. The left-to-right (L/R) ratio was used as an index of the relative kidney function. Mean L/R values were calculated for four follow-up time intervals. For all patients, kidney V20 (percentage of the volume of the kidney that received more than 20 Gy) and mean dose of both kidneys were retrieved from the three-dimensional dose-volume histograms.
Results: We observed a progressive decrease in left renal function of 11% (p = 0.012) after 6 months, up to 52% (p < 0.001) after >18 months. The V20 (left kidney) and mean left kidney dose were identified as parameters associated with decreased kidney function. Mean serum creatinine was increased from 74.6 micromol/L before treatment to 86.1 micromol/L at 1 year after chemoradiotherapy (p < 0.001). In patients with a follow-up of 18-28 months, one case of severe renovascular hypertension was observed.
Conclusion: A progressive relative functional impairment of the left kidney in patients after postoperative chemoradiotherapy for gastric cancer is demonstrated. To optimize the survival benefit that can be established with adjuvant regimens, strategies to minimize the dose to the kidneys and other critical organs should be explored.
Similar articles
-
Renal toxicity of adjuvant chemoradiotherapy with cisplatin in gastric cancer.Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1429-35. doi: 10.1016/j.ijrobp.2007.05.021. Epub 2007 Aug 9. Int J Radiat Oncol Biol Phys. 2007. PMID: 17692474 Clinical Trial.
-
Combined adjuvant radiochemotherapy with IMRT/XELOX improves outcome with low renal toxicity in gastric cancer.Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1187-95. doi: 10.1016/j.ijrobp.2008.12.036. Epub 2009 May 4. Int J Radiat Oncol Biol Phys. 2009. PMID: 19409725
-
Comparison of changes in renal function with dosimetric parameters in gastric cancer patients treated with adjuvant chemoradiotherapy.Jpn J Radiol. 2017 Dec;35(12):733-739. doi: 10.1007/s11604-017-0692-1. Epub 2017 Oct 24. Jpn J Radiol. 2017. PMID: 29064001
-
[Role of adjuvant chemoradiotherapy in the treatment of gastric carcinoma].Cas Lek Cesk. 2003;142 Suppl 1:26-8. Cas Lek Cesk. 2003. PMID: 12924046 Review. Czech.
-
Role of (chemo)-radiotherapy in resectable gastric cancer.Clin Oncol (R Coll Radiol). 2014 Sep;26(9):541-50. doi: 10.1016/j.clon.2014.06.004. Epub 2014 Jul 1. Clin Oncol (R Coll Radiol). 2014. PMID: 24996375 Review.
Cited by
-
β-elemene enhances the radiosensitivity of gastric cancer cells by inhibiting Pak1 activation.World J Gastroenterol. 2015 Sep 14;21(34):9945-56. doi: 10.3748/wjg.v21.i34.9945. World J Gastroenterol. 2015. PMID: 26379399 Free PMC article.
-
[Functional magnetic resonance imaging for evaluation of radiation-induced renal damage].Radiologe. 2012 Mar;52(3):243-51. doi: 10.1007/s00117-011-2195-x. Radiologe. 2012. PMID: 22374084 German.
-
Dosimetric comparison of intensity modulated and volumetric arc radiation therapy for gastric cancer.Oncol Lett. 2014 Oct;8(4):1427-1434. doi: 10.3892/ol.2014.2363. Epub 2014 Jul 18. Oncol Lett. 2014. PMID: 25202345 Free PMC article.
-
Dosimetric Comparison of Three Different Radiotherapy Techniques in Antrum-Located Stomach Cancer.Asian Pac J Cancer Prev. 2017 Mar 1;18(3):741-746. doi: 10.22034/APJCP.2017.18.3.741. Asian Pac J Cancer Prev. 2017. PMID: 28441708 Free PMC article.
-
Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer.Strahlenther Onkol. 2013 May;189(5):417-23. doi: 10.1007/s00066-013-0309-2. Epub 2013 Apr 6. Strahlenther Onkol. 2013. PMID: 23558673 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical